Gilead Sciences, Inc. GILD

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
70/100
Moderate

Ranked against 19 peers in Drug Manufacturers - General

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and … Full GILD analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.83), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.97), indicating reliable business model.

Key risks

  • Volatile Margins Suggest Cyclicality Margin volatility is high (stability score 0.28), suggesting cyclical exposure or competitive pressure.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
58
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where GILD ranks in Drug Manufacturers - General

Gilead Sciences, Inc. ranks #3 of 20 scored companies in Drug Manufacturers - General by moat score — the top 15%. The widest moat in the group is Novo Nordisk A/S (NVO) at 74/100.

# Company Moat score Rating
1 Novo Nordisk A/S NVO 74/100 Moderate
2 Novartis AG NVS 73/100 Moderate
3 Gilead Sciences, Inc. GILD 70/100 Moderate
4 Merck & Company, Inc. MRK 67/100 Moderate
5 Johnson & Johnson JNJ 67/100 Moderate
6 Bristol-Myers Squibb Company BMY 66/100 Moderate
7 Biogen Inc. BIIB 61/100 Moderate
8 Amgen Inc. AMGN 55/100 Moderate
9 Sanofi SNY 54/100 Moderate

See every Pharma / Mature Biotech company ranked by moat score →

How GILD scores on the Corporate Default defenses

Pricing Power

Score 58 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 83 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 90 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 67 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 68 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 61 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding GILD's moat

What is Gilead Sciences, Inc.'s moat score?

Gilead Sciences, Inc. (GILD) scores 70 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #3 of 20 scored companies in Drug Manufacturers - General, the top 15%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Customer Stickiness (90/100) and its weakest is Pricing Power (58/100).

How does Gilead Sciences, Inc. compare with other Drug Manufacturers - General companies?

Gilead Sciences, Inc. ranks #3 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Novartis AG (NVS) at 72 just above it and Merck & Company, Inc. (MRK) at 67 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.

Why is Gilead Sciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Gilead Sciences, Inc.?

The Corporate Default template measures 6 defenses, and GILD scores: Pricing Power (58), Cost Advantage (83), Customer Stickiness (90), Capital Efficiency (67), Resilience (68), Scale & Market Position (61). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000